Faruqi & Faruqi Investigates Atara Biotherapeutics for Securities Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ATRA?
Source: PRnewswire
- Investor Rights Protection: Faruq & Faruqi, LLP is investigating potential securities claims against Atara Biotherapeutics, specifically for investors who purchased the company's securities between May 20, 2024, and January 9, 2026.
- Legal Consultation Opportunity: The firm encourages affected investors to contact partner Josh Wilson directly for legal options, reachable at 877-247-4292 or 212-983-9330 (Ext. 1310).
- Class Action Reminder: Investors should note that a federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff to protect their rights.
- Potential Impact Assessment: This investigation may negatively affect Atara's stock price and investor confidence, prompting investors to closely monitor developments to make informed decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.770
Low
18.00
Averages
21.50
High
25.00
Current: 4.770
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Atara Biotherapeutics for Securities Claims
- Investor Rights Protection: Faruq & Faruqi, LLP is investigating potential securities claims against Atara Biotherapeutics, specifically for investors who purchased the company's securities between May 20, 2024, and January 9, 2026.
- Legal Consultation Opportunity: The firm encourages affected investors to contact partner Josh Wilson directly for legal options, reachable at 877-247-4292 or 212-983-9330 (Ext. 1310).
- Class Action Reminder: Investors should note that a federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff to protect their rights.
- Potential Impact Assessment: This investigation may negatively affect Atara's stock price and investor confidence, prompting investors to closely monitor developments to make informed decisions.
See More
Atara Biotherapeutics Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Atara Biotherapeutics, encouraging those who purchased ATRA shares between May 20, 2024, and January 9, 2026, to contact the firm regarding potential lead plaintiff appointment, highlighting the legal risks surrounding the company.
- Allegations Overview: The complaint alleges that during the class period, Atara made materially false and misleading statements, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel and could significantly impact the company's financial condition.
- Increased Regulatory Risk: The manufacturing issues have subjected Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but may also diminish investor confidence in the company's future, potentially affecting stock performance.
- Shareholder Action Deadline: Shareholders must register by May 22, 2026, to participate in this class action lawsuit, and failure to register in time may result in missed recovery opportunities, reflecting the legal challenges the company faces and their potential impact on shareholders.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Lawsuit Overview: Lufax Holding Ltd. faces a class action for the period from April 7, 2023, to January 26, 2025, due to undisclosed internal control deficiencies and misstated financial results, with a lead plaintiff deadline of May 20, 2026, potentially impacting the company's reputation and stock price.
- Atara Biotechnology Issues: Atara Biotherapeutics, Inc. is involved in a class action for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that overstated FDA approval prospects, with a lead plaintiff deadline of May 22, 2026, likely to have a significant negative impact on the company's financial condition.
- Coty Performance Decline: Coty Inc. is facing a class action for the period from November 5, 2025, to February 4, 2026, due to undisclosed underperformance in its Consumer Beauty segment and slowing market growth, with a lead plaintiff deadline of May 22, 2026, which may affect the company's future market performance.
- Legal Consultation Opportunity: Investors are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights and explore participation in these class actions, indicating that the legal risks faced by these companies could impact shareholder confidence and market performance.
See More
Reminder for Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which significantly impacted investors and the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019, showcasing its strong track record in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven success record, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Lawsuit Background: Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, alleging the company made false and misleading statements that affected investor decisions.
- Allegation Details: The lawsuit claims that Atara faced manufacturing issues and deficiencies in the ALLELE study, making it unlikely that the FDA would approve the tabelecleucel Biologics License Application, which could significantly negatively impact the company's financial condition and business prospects.
- Investor Rights: Affected investors must apply by May 22, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to help investors understand their rights and options.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, boasting extensive litigation experience and a nationwide practice.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California, targeting investors who purchased Atara securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- Detailed Allegations: The lawsuit alleges that Atara issued false and misleading statements while failing to disclose material adverse facts regarding its business, operations, and prospects, particularly concerning the regulatory outlook for the tabelecleucel Biologics License Application.
- Impact of Manufacturing Issues: The lawsuit highlights manufacturing problems and deficiencies in the ALLELE study that may hinder FDA approval of tabelecleucel, likely resulting in significant negative impacts on Atara's business and financial condition.
- Investor Action Call: Affected investors are encouraged to apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit, reflecting the potential financial and reputational risks facing the company.
See More
Faruqi & Faruqi Investigates Atara Biotherapeutics for Securities Claims
- Investor Rights Protection: Faruq & Faruqi, LLP is investigating potential securities claims against Atara Biotherapeutics, specifically for investors who purchased the company's securities between May 20, 2024, and January 9, 2026.
- Legal Consultation Opportunity: The firm encourages affected investors to contact partner Josh Wilson directly for legal options, reachable at 877-247-4292 or 212-983-9330 (Ext. 1310).
- Class Action Reminder: Investors should note that a federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff to protect their rights.
- Potential Impact Assessment: This investigation may negatively affect Atara's stock price and investor confidence, prompting investors to closely monitor developments to make informed decisions.
See More
Atara Biotherapeutics Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Atara Biotherapeutics, encouraging those who purchased ATRA shares between May 20, 2024, and January 9, 2026, to contact the firm regarding potential lead plaintiff appointment, highlighting the legal risks surrounding the company.
- Allegations Overview: The complaint alleges that during the class period, Atara made materially false and misleading statements, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel and could significantly impact the company's financial condition.
- Increased Regulatory Risk: The manufacturing issues have subjected Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but may also diminish investor confidence in the company's future, potentially affecting stock performance.
- Shareholder Action Deadline: Shareholders must register by May 22, 2026, to participate in this class action lawsuit, and failure to register in time may result in missed recovery opportunities, reflecting the legal challenges the company faces and their potential impact on shareholders.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Lawsuit Overview: Lufax Holding Ltd. faces a class action for the period from April 7, 2023, to January 26, 2025, due to undisclosed internal control deficiencies and misstated financial results, with a lead plaintiff deadline of May 20, 2026, potentially impacting the company's reputation and stock price.
- Atara Biotechnology Issues: Atara Biotherapeutics, Inc. is involved in a class action for the period from May 20, 2024, to January 9, 2026, alleging undisclosed manufacturing issues and clinical trial risks that overstated FDA approval prospects, with a lead plaintiff deadline of May 22, 2026, likely to have a significant negative impact on the company's financial condition.
- Coty Performance Decline: Coty Inc. is facing a class action for the period from November 5, 2025, to February 4, 2026, due to undisclosed underperformance in its Consumer Beauty segment and slowing market growth, with a lead plaintiff deadline of May 22, 2026, which may affect the company's future market performance.
- Legal Consultation Opportunity: Investors are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights and explore participation in these class actions, indicating that the legal risks faced by these companies could impact shareholder confidence and market performance.
See More
Reminder for Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which significantly impacted investors and the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019, showcasing its strong track record in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven success record, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Lawsuit Background: Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, alleging the company made false and misleading statements that affected investor decisions.
- Allegation Details: The lawsuit claims that Atara faced manufacturing issues and deficiencies in the ALLELE study, making it unlikely that the FDA would approve the tabelecleucel Biologics License Application, which could significantly negatively impact the company's financial condition and business prospects.
- Investor Rights: Affected investors must apply by May 22, 2026, to be appointed as lead plaintiff in the lawsuit, with Bragar Eagel & Squire offering no-cost legal consultations to help investors understand their rights and options.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in representing individual and institutional investors in securities, derivative, and commercial litigation, boasting extensive litigation experience and a nationwide practice.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California, targeting investors who purchased Atara securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- Detailed Allegations: The lawsuit alleges that Atara issued false and misleading statements while failing to disclose material adverse facts regarding its business, operations, and prospects, particularly concerning the regulatory outlook for the tabelecleucel Biologics License Application.
- Impact of Manufacturing Issues: The lawsuit highlights manufacturing problems and deficiencies in the ALLELE study that may hinder FDA approval of tabelecleucel, likely resulting in significant negative impacts on Atara's business and financial condition.
- Investor Action Call: Affected investors are encouraged to apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit, reflecting the potential financial and reputational risks facing the company.
See More
